Cholangiocarcinoma Foundation congratulates AstraZeneca TOPAZ-1, the first Phase III trial to show adding immunotherapy to standard chemotherapy can increase overall survival in advanced biliary tract cancer
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
